Wedbush analyst David Nierengarten initiated coverage of Vor Bio with an Outperform rating and $18 price target. The stock in after-hours trading is up 12% to $5.07. The analyst has a positive outlook for the company’s “differentiated” approach to engineered hematopoietic stem cell transplants, which he notes currently remains the only curative treatment option for acute myeloid leukemia. Vor’s lead asset, VOR33, has the potential to change stem cell transplant practice in AML and other hematological malignancies due to its myelo-protective potential, Nierengarten tells investors in a research note. The analyst adds that VCAR33 could emerge as a superior post-transplant treatment option for AML patients over current salvage therapies.
previous post
next post